Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

h patient receiving ANA598 would receive two 800 mg doses on day one, known as a loading dose. The decision to initiate dosing of patients in the 400 mg dose group will be determined after assessing 28 day data from the 200 mg dose group. Anadys intends to enroll 90 patients in this study, in the proportions of 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study will be conducted at a number of clinical sites in the United States.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' restructuring plans, its focus of operations, management of its ANA773 programs, its plans regarding the planned ANA598 Phase II trial, the potency, safety and tolerability profile of ANA598, which may not be duplicated in future clinical studies of longer duration, the planned timing for initiating the Phase II trial of ANA598, the proposed design of the ANA598 trial, the expected timing and occurrence of projected ANA598 Phase II data milestones, the Company's reduction of its workforce, its ability to retain personnel, its ability to achieve cost-savings in c
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 METTLER TOLEDO is ... pallet measuring device CNS110 ScanTape™ . Replacing ... entry, offering greater ease and accuracy for transport ... can significantly enhance productivity—an important benefit for load ... volume equals profits. , Usable at any ...
(Date:9/21/2014)... at the University of Basel in Switzerland have ... a charged molecule for the first time. These ... measurements of molecular properties and may also contribute ... technology. The results were published in the scientific ... study of the interaction between matter and light, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
Breaking Biology Technology:ScanTape™ Handheld Dimensioner Increases Processing Volume 2Uncovering the forbidden side of molecules 2Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... , CAMBRIDGE, Mass., Dec. ... leaders in technology development and product integration in cleantech, ... for technology abstracts and business presentations. , Now in ... Nano Science and Technology Institute (NSTI), and the Clean ...
... RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- ... EMDY), a leading,producer and distributor of infant and children,s formula, ... Company will be featured,in the Spring issue of US Food ... 250,000 executives in the food and beverage industry. , ...
... , ... through,extraordinary times; markets are in turmoil and uncertainty is part ... industry has been,relatively immune to the economic downturn, because illness ... midst of the difficult times this year, the pharmaceutical,giant Johnson ...
Cached Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
(Date:9/21/2014)... San Diego, have developed a program that predicts the ... genes based on sequences of DNA. They describe their ... embryonic cells in a paper published in Nature ... cells have the same blueprint, the same DNA, although ... of the report. "Skin cells protect, nerve cells send ...
(Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
(Date:9/21/2014)... researchers has developed a protein therapy that disrupts the ... original tumor sites, travel through the blood stream and ... This process, known as metastasis, can cause cancer to ... patients who succumb to cancer fall prey to metastatic ... professor of bioengineering who describes a new therapeutic approach ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Island Hospital researcher has found that the use of electronic ... on the demand for drug treatment programs and how prescribers ... Traci C. Green, Ph.D., MSc, research scientist in Rhode Island ... advance of print in the journal Pain Medicine . ...
... Aug. 16, 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ) ... their Safe Storage and Access Lockers as other major companies ... "When a company as large as Amazon introduces ... educate the public about the usefulness and benefits of the ...
... countries will experience more extreme floods and droughts, in ... paper out today in the journal Nature . ... rain band responding to greenhouse warming. The South Pacific ... Southern Hemisphere spanning the Pacific from south of the ...
Cached Biology News:RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse 2RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse 3Medbox Safe Storage and Access Lockers Gaining Popularity 2Warming causes more extreme shifts of the Southern Hemisphere's largest rain band 2
... Agencourt offers single pass sequencing of ... is fueled by our high performance ... million Phred20 bases per day. The ... pass sequencing customers are rapid turnaround, ...
... Facility , Galaxy LIMS, Sophisticated Bioinformatics , ... scientists ,We offer individual sample sequencing of ... for single or double strand publication quality. ... DNA of interest is 1.3 to 7 ...
... sequencing of individual research samples, including PCR ... Agencourt's world-class, high performance sequencing pipeline processes ... The key benefits of Agencourt's QuickLane ... 48 hour sample turnaround, industry leading sequence ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
Biology Products: